Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 1308
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT00165438 | Pulmonary Function in Patients With Hodgkin's Disease Receiving Bleomycin-Based Chemotherapy | ||
| NCT00441142 | Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors | ||
| NCT03070145 | Exercise Intervention Among Men With Prostate Cancer Initiating Androgen Deprivation Therapy | ||
| NCT01582841 | Integrating Genetic Testing for Lynch Syndrome in a Managed Care Setting | ||
| NCT02943642 | Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein in Subjects With Mycosis Fungoides | ||
| NCT00130702 | Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia | ||
| NCT00782275 | Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma | ||
| NCT00153907 | Navelbine and Capecitabine in the Treatment of Metastatic Breast Cancer | ||
| NCT00307736 | Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer | ||
| NCT06518564 | Avelumab and M1774 in ARID1A-mutated Endometrial Cancer | ||
| NCT04040725 | Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression | ||
| NCT03161431 | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | ||
| NCT02176031 | Phase II Trial of Natalizumab + Prednisone for Initial Therapy of Acute GI GVHD | ||
| NCT00376480 | Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant | ||
| NCT01921335 | ARRY-380 + Trastuzuamab for Breast w/ Brain Mets | ||
| NCT01024946 | Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity | ||
| NCT07624513 | Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma | ||
| NCT00593060 | Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer | ||
| NCT02523040 | Lenalidomide for Adult Histiocyte Disorders | ||
| NCT01659203 | Proton or Photon RT for Retroperitoneal Sarcomas | ||
| NCT02022982 | PALBOCICLIB + PD-0325901 for NSCLC & Solid Tumors | ||
| NCT07232043 | ACTIVATE: AI-driven Clinical-trial Trial-Information and Viability Assessment Tool for EHRs | ||
| NCT00520013 | Avastin +/- Erlotinib Consolidation Chemotherapy After Carboplatin, Paclitaxel, and Avastin (CTA) Induction Therapy for Advanced Ovarian, Fallopian Tube, Primary Peritoneal Cancer & Papillary Serous or Clear Cell Mullerian Tumors | ||
| NCT02644382 | Improving Surgical Decision-making in Young Women With Breast Cancer | ||
| NCT00821080 | Vandetanib and Sirolimus in Patients With Recurrent Glioblastoma | ||
| NCT02919670 | A Study Evaluating a Proprietary Amino Acid Mixture (Enterade®) in Patients Receiving High-Dose Melphalan Conditioning Followed by Autologous Stem Cell Transplantation for Multiple Myeloma and Non-Hodgkin Lymphoma | ||
| NCT00020670 | Vaccine Therapy in Treating Patients With Acute Lymphoblastic Leukemia | ||
| NCT01078961 | An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma | ||
| NCT03514680 | Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy | ||
| NCT01294670 | Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors | ||
| NCT03277482 | Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer | ||
| NCT03482557 | Contrast Enhanced Spectral Mammography vs. MRI for Breast Cancer Screening | ||
| NCT05632328 | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC | ||
| NCT00590902 | Ph II OSI-774 (Erlotinib,Tarceva) In Advanced Bronchioloalveolar Cell Lung Cancer | ||
| NCT00119730 | Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma | ||
| NCT00137813 | Avastin and Taxotere for Esophagogastric Cancer | ||
| NCT00525460 | Young Women Diagnosed With Early Stage Ovarian Cancer: A Focus on Fertility Issues and Sexual Function | ||
| NCT03789110 | NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer | ||
| NCT02423148 | Pilot Study of Novel Fluorescence Endoscopic Device for Sentinel Lymph Node Mapping in Lung Cancer | ||
| NCT06565052 | The Impact of PReOPerative Exercise and NutritionaL Optimization on Perioperative Outcomes for Patients Undergoing Treatment for Rectal Cancer: The PROPEL Trial | ||
| NCT00585078 | Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma | ||
| NCT00859040 | Monthly SOM230C for Recurrent or Progressive Meningioma | ||
| NCT01647607 | Young and Strong: An Education and Supportive Care Intervention Study for Young Women With Breast Cancer | ||
| NCT02279004 | A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care | ||
| NCT06758102 | Dance Study for Post-surgical Pain in Breast Cancer Survivors | ||
| NCT00165581 | High Dose Rate Intracavitary Brachytherapy as the Sole Method of Radiation Therapy for Breast Carcinoma | ||
| NCT01838564 | The PediQUEST Study: Evaluation of Pediatric Quality of Life and Evaluation of Symptoms Technology | ||
| NCT00542451 | Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer | ||
| NCT03410875 | A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | ||
| NCT03289039 | Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer |
